Pharmacogenetics of antipsychotics: Recent progress and methodological issues

Expert Opinion on Drug Metabolism and Toxicology

Volumn 9, Issue 2, 2013, Pages 183-191

  Zhang, Jian Ping ^a   Malhotra, Anil K ^a  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

Author keywords

Antipsychotic; Clinical application; Pharmacogenetics; Schizophrenia

Indexed keywords

ALANINE; ARIPIPRAZOLE; CLOZAPINE; CYSTEINE; CYTOCHROME P450 2D6; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 70-2; HLA DQB1 ANTIGEN; LEPTIN; MYELOPEROXIDASE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RISPERIDONE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AGRANULOCYTOSIS; ALLELE; AMINO ACID SUBSTITUTION; BODY MASS; DRUG FATALITY; DRUG METABOLISM; DRUG WITHDRAWAL; FAT MASS; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; INFECTION; METABOLIC SYNDROME X; NEUTROPHIL COUNT; NONHUMAN; PATHOPHYSIOLOGY; PHARMACOGENETICS; PHENOTYPE; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; WEIGHT GAIN;

ANIMALS; ANTIPSYCHOTIC AGENTS; HUMANS; PHARMACOGENETICS; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 84872440175     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2013.736964     Document Type: Review

References (57)

1. Zhang JP, Malhotra AK. Pharmacogenetics and antipsychotics: ktherapeutic efficacy and side effects prediction. Expert Opin Drug Metab Toxicol 2011;7(1):9-37
2. Pramyothin P, Khaodhiar L. Metabolic syndrome with the atypical antipsychotics. Curr Opin Endocrinol Diabetes Obesity 2010;17(5):460-6
3. Comuzzie AG, Allison DB. The search for human obesity genes. Science (New York, Y) 1998;280(5368):1374-7 (Pubitemid 28264818)
4. Allison DB, Kaprio J, Korkeila M, et al. The heritability of body mass index among an international sample of monozygotic twins reared apart. Int J Obes Relat Metab Disord 1996;20(6):501-6 (Pubitemid 26174333)
5. Renstrom F, Payne F, Nordstrom A, et al. Replication and extension of genome-wide association study results for obesity in 4923 adults from northern Sweden. Hum Mol Genet 2009;18(8):1489-96
6. Lett TA, Wallace TJ, Chowdhury NI, et al. Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. Mol Psychiatry 2012;17(3):242-66
7. Muller DJ, Zai CC, Sicard M, et al. Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain. Pharmacogenomics J 2010;12(2):156-64
8. Lencz T, Robinson DG, Napolitano B, et al. DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia. Pharmacogenet Genomics 2010;20(9):569-72
9. Hong CJ, Liou YJ, Bai YM, et al. Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment. Pharmacogenet Genomics 2010;20(6):359-66
10. Reynolds GP, Zhang ZJ, Zhang XB. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 2002;359(9323):2086-7 (Pubitemid 34680975)
11. Sicard MN, Zai CC, Tiwari AK, et al. Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis. Pharmacogenomics 2010;11(11):1561-71
12. Souza RP, De Luca V, Muscettola G, et al. Association of antipsychotic induced weight gain and body mass index with GNB3 gene: a meta-analysis. Prog neuropsychopharmacol Biol Psychiatry 2008;32(8):1848-53
13. Park YM, Chung YC, Lee SH, et al. G-protein beta3 subunit gene 825C/T polymorphism is not associated with olanzapine-induced weight gain in Korean schizophrenic patients. Psychiatry Investig 2009;6(1):39-43
14. Adkins DE, Aberg K, McClay JL, et al. Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs. Mol Psychiatry 2010;16:321-32
15. Malhotra AK, Correll CU, Chowdhury NI, et al. Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. Arch Gen Psychiatry 2012; [Epub ahead of print]
16. Correll CU, Malhotra AK. Pharmacogenetics of antipsychotic-induced weight gain. Psychopharmacology (Berl) 2004;174(4):477-89 (Pubitemid 39119337)
17. Zhang JP, Weiss JJ, McCardle M, et al. Effectiveness of a cognitive behavioral weight management intervention in obese patients with psychotic disorders compared to patients with nonpsychotic disorders or no psychiatric disorders: results from a 12-month, real-world study. J Clin Psychopharmacol 2012;32(4):458-64
18. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45(9):789-96
19. McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006;163(4):600-10 (Pubitemid 44464569)
20. Meltzer HY. Treatment-resistant schizophrenia - the role of clozapine. Curr Med Res Opin 1997;14(1):1-20 (Pubitemid 28080714)
21. Kane JM, Leucht S, Carpenter D, et al. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 2003;64(Suppl 12):5-19
22. Honigfeld G, Arellano F, Sethi J, et al. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry 1998;59(Suppl 3):3-7 (Pubitemid 28196363)
23. Hsuanyu Y, Dunford HB. Oxidation of clozapine and ascorbate by myeloperoxidase. Arch Biochem Biophys 1999;368(2):413-20 (Pubitemid 29406569)
24. Lieberman JA, Yunis J, Egea E, et al. HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Arch Gen Psychiatry 1990;47(10):945-8 (Pubitemid 20348482)
25. Purcell SM, Wray NR, Stone JL, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009;460(7256):748-52
26. Stefansson H, Ophoff RA, Steinberg S, et al. Common variants conferring risk of schizophrenia. Nature 2009;460(7256):744-7
27. Yunis JJ, Corzo D, Salazar M, et al. HLA associations in clozapine-induced agranulocytosis. Blood 1995;86(3):1177-83
28. Corzo D, Yunis JJ, Salazar M, et al. The major histocompatibility complex region marked by HSP70-1 and HSP70-2 variants is associated with clozapine-induced agranulocytosis in two different ethnic groups. Blood 1995;86(10):3835-40
29. Turbay D, Lieberman J, Alper CA, et al. Tumor necrosis factor constellation polymorphism and clozapine-induced agranulocytosis in two different ethnic groups. Blood 1997;89(11):4167-74 (Pubitemid 27220966)
30. Dettling M, Schaub RT, Mueller-Oerlinghausen B, et al. Further evidence of human leukocyte antigen-encoded susceptibility to clozapine-induced agranulocytosis independent of ancestry. Pharmacogenetics 2001;11(2):135-41 (Pubitemid 32216124)
31. Mosyagin I, Cascorbi I, Schaub R, et al. Drug-induced agranulocytosis: impact of different fcgamma receptor polymorphisms? J Clin Psychopharmacol 2005;25(5):435-40 (Pubitemid 41368365)
32. Ostrousky O, Meged S, Loewenthal R, et al. NQO2 gene is associated with clozapine-induced agranulocytosis. Tissue Antigens 2003;62(6):483-91 (Pubitemid 37475996)
33. Athanasiou MC, Dettling M, Cascorbi I, et al. Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis. J Clin Psychiatry 2011;72(4):458-63
34. Volpi S, Potkin SG, Malhotra AK, et al. Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia. J Clin Psychiatry 2009;70(6):801-9
35. Malhotra AK, Lencz T, Correll CU, et al. Genomics and the future of pharmacotherapy in psychiatry. Int Rev Psychiatry (Abingdon, England) 2007;19(5):523-30
36. Zhang JP, Lencz T, Malhotra AK. D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. Am J Psychiatry 2010;167(7):763-72
37. Tsai SJ, Hong CJ, Yu YW, et al. -759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain. Lancet 2002;360(9347):1790
38. Theisen FM, Hinney A, Bromel T, et al. Lack of association between the -759C/T polymorphism of the 5-HT2C receptor gene and clozapine-induced weight gain among German schizophrenic individuals. Psychiatr Genet 2004;14(3):139-42 (Pubitemid 39281820)
39. Miller DD, Ellingrod VL, Holman TL, et al. Clozapine-induced weight gain associated with the 5HT2C receptor -759C/T polymorphism. Am J Med Genet B Neuropsychiatr Genet 2005;133B(1):97-100 (Pubitemid 40175624)
40. Ellingrod VL, Perry PJ, Ringold JC, et al. Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine. Am J Med Genet B Neuropsychiatr Genet 2005;134B(1):76-8 (Pubitemid 40411114)
41. Park YM, Cho JH, Kang SG, et al. Lack of association between the -759C/T polymorphism of the 5-HT2C receptor gene and olanzapine-induced weight gain among Korean schizophrenic patients. J Clin Pharm Ther 2008;33(1):55-60
42. Templeman LA, Reynolds GP, Arranz B, et al. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genomics 2005;15(4):195-200 (Pubitemid 40569890)
43. Ryu S, Cho EY, Park T, et al. -759 C/T polymorphism of 5-HT2C receptor gene and early phase weight gain associated with antipsychotic drug treatment. Prog Neuropsychopharmacol Biol Psychiatry 2007;31(3):673-7 (Pubitemid 46467047)
44. Godlewska BR, Olajossy-Hilkesberger L, Ciwoniuk M, et al. Olanzapine-induced weight gain is associated with the -759C/T and -697G/C polymorphisms of the HTR2C gene. Pharmacogenomics J 2009;9(4):234-41
45. Julius RJ, Novitsky MA Jr, Dubin WR. Medication adherence: a review of the literature and implications for clinical practice. J Psychiatr Pract 2009;15(1):34-44
46. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209-23 (Pubitemid 41345943)
47. Malhotra AK, Zhang JP, Lencz T. Pharmacogenetics in psychiatry: translating research into clinical practice. Mol Psychiatry 2012;17(8):760-9
48. Velligan DI, Weiden PJ, Sajatovic M, et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 2009;70(Suppl 4):1-46; quiz 7-8
49. Simon GE, Perlis RH. Personalized medicine for depression: can we match patients with treatments? Am J Psychiatry 2010;167(12):1445-55
50. Kirchheiner J, Fuhr U, Brockmoller J. Pharmacogenetics-based therapeutic recommendations-ready for clinical practice? Nat Rev Drug Discov 2005;4(8):639-47 (Pubitemid 41149757)
51. Claas FH, Abbott PA, Witvliet MD, et al. No direct clinical relevance of the human leucocyte antigen (HLA) system in clozapine-induced agranulocytosis. Drug Saf 1992;7(Suppl 1):3-6
52. Valevski A, Klein T, Gazit E, et al. HLA-B38 and clozapine-induced agranulocytosis in Israeli Jewish schizophrenic patients. Eur J Immunogenet 1998;25(1):11-13 (Pubitemid 28154401)
53. Amar A, Segman RH, Shtrussberg S, et al. An association between clozapine-induced agranulocytosis in schizophrenics and HLA-DQB1.*0201. Int J Neuropsychopharmacol 1998;1(1):41-4 (Pubitemid 128538364)
54. Dettling M, Cascorbi I, Roots I, et al. Genetic determinants of clozapine-induced agranulocytosis: recent results of HLA subtyping in a non-jewish caucasian sample. Arch Gen Psychiatry 2001;58(1):93-4 (Pubitemid 32057770)
55. Dettling M, Sachse C, Muller-Oerlinghausen B, et al. Clozapine-induced agranulocytosis and hereditary polymorphisms of clozapine metabolizing enzymes: no association with myeloperoxidase and cytochrome P4502D6. Pharmacopsychiatry 2000;33(6):218-20
56. Mosyagin I, Dettling M, Roots I, et al. Impact of myeloperoxidase and NADPH-oxidase polymorphisms in drug-induced agranulocytosis. J Clin Psychopharmacol 2004;24(6):613-17 (Pubitemid 39518656)
57. Dettling M, Cascorbi I, Opgen-Rhein C, et al. Clozapine-induced agranulocytosis in schizophrenic Caucasians: confirming clues for associations with human leukocyte class I and II antigens. Pharmacogenomics J 2007;7(5):325-32 (Pubitemid 47471310)